Michael Hayden, Prilenia CEO
November 3, 2021 07:00 AM EDT
Financing

Go­ing af­ter Hunt­ing­ton's dis­ease again, ex-Te­va R&D chief gets some cash for Prile­ni­a's re­newed ef­forts

Max Gelman

Senior Editor

Even while serv­ing as the glob­al R&D head for Te­va sev­er­al years ago, Michael Hay­den had high hopes for a drug known as pri­do­pi­dine. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

A service from the Financial Times